Literature DB >> 24371606

Prolonged response to trabectedin in a heavily pretreated patient with metastatic endometrial carcinoma: A case report and literature review.

Giulia Meoni1, Fabiana Letizia Cecere1, Imane Chaib2, Elisa Giommoni1, Francesco Di Costanzo1.   

Abstract

► We report the case of a heavily pretreated woman affected by metastatic endometrial carcinoma. ► Patient received Trabectedin as 10th line of treatment with an impressive clinical response. ► We evaluated BRCA1 and ERCC1 gene status which could be involved in Trabectedin sensitivity.

Entities:  

Keywords:  BRCA1; Chemotherapy; ERCC1; Endometrial carcinoma; Trabectedin

Year:  2011        PMID： 24371606      PMCID： PMC3860796          DOI： 10.1016/j.gynor.2011.11.008

Source DB:  PubMed          Journal:  Gynecol Oncol Case Rep        ISSN： 2211-338X


  4 in total

1.  ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.

Authors:  Antoine Italiano; Armelle Laurand; Audrey Laroche; Paolo Casali; Roberta Sanfilippo; Axel Le Cesne; Ian Judson; Jean-Yves Blay; Isabelle Ray-Coquard; Binh Bui; Jean-Michel Coindre; Antonio Nieto; Juan-Carlos Tercero; Jose Jimeno; Jacques Robert; Philippe Pourquier
Journal:  Cancer       Date:  2011-02-01       Impact factor: 6.860

2.  Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.

Authors:  P Schöffski; M Taron; J Jimeno; F Grosso; R Sanfilipio; P G Casali; A Le Cesne; R L Jones; J-Y Blay; A Poveda; R G Maki; A Nieto; J C Tercero; R Rosell
Journal:  Eur J Cancer       Date:  2011-03-04       Impact factor: 9.162

3.  Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.

Authors:  George D Demetri; Sant P Chawla; Margaret von Mehren; Paul Ritch; Laurence H Baker; Jean Y Blay; Kenneth R Hande; Mary L Keohan; Brian L Samuels; Scott Schuetze; Claudia Lebedinsky; Yusri A Elsayed; Miguel A Izquierdo; Javier Gómez; Youn C Park; Axel Le Cesne
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

4.  Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.

Authors:  D S McMeekin; A Lisyanskaya; M Crispens; A M Oza; P Braly; D Doering; E Bayever; B Michiels; M Markman
Journal:  Gynecol Oncol       Date:  2009-05-23       Impact factor: 5.482
  4 in total
  1 in total

Review 1.  Synthetic strategies to terpene quinones/hydroquinones.

Authors:  Marina Gordaliza
Journal:  Mar Drugs       Date:  2012-02-14       Impact factor: 6.085
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.